Status:
COMPLETED
An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World Practice
Lead Sponsor:
AbbVie
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. Despite the range of treatment options for RA steadily increasing, many patien...
Eligibility Criteria
Inclusion
- Diagnosis of moderate to severe active rheumatoid arthritis (RA) upon judgment of the treating physician.
- Upadacitinib prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies and upadacitinib treatment was started within 1 week before the enrollment.
- Physician decision on participant treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
Exclusion
- Participants who cannot be treated with upadacitinib as per SmPC or local prescription criteria.
- Prior treatment course with upadacitinib or the current upadacitinib treatment was started more than 1 week prior to enrollment.
- Participant currently participating in any interventional study.
Key Trial Info
Start Date :
April 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 22 2024
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT05327920
Start Date
April 20 2022
End Date
April 22 2024
Last Update
March 14 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 234201
Győr, Győr-Moson-Sopron, Hungary, 9024
2
Debreceni Egyetem-Klinikai Kozpont /ID# 246156
Debrecen, Hajdú-Bihar, Hungary, 4032
3
Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz /ID# 234204
Budapest, Hungary, 1023
4
Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz /ID# 239231
Gyula, Hungary, 5700